Digital health, diagnostics, and medical devices—signals that matter for adoption, reimbursement, and outcomes.
Implantica has secured FDA approval for RefluxStop, its gastroesophageal reflux disease implant, opening access to a U.S. market the company says includes around 78 million patients. The next question is not regulatory clearance but how quickly the company can build trained sites and surgeon adoption.
Implantica has secured FDA approval for RefluxStop, its gastroesophageal reflux disease implant, opening access to a U.S. market the company says includes around 78 million patients. The next question is not regulatory clearance but how quickly the company can build trained sites and surgeon adoption.
READ MORE
Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a blood test intended to help rule in and rule out Alzheimer’s-linked amyloid pathology in people 55 and older with cognitive decline. Roche said it is the first FDA-cleared single-biomarker blood test to support both uses across primary and specialty care settings.
Focal therapy is drawing more interest in localized prostate cancer because it can target MRI-visible lesions with fewer side effects than surgery or radiation. But U.S. guidelines still classify the approach as experimental and uptake remains low.
New U.K. data are giving focal therapy supporters stronger long-term survival numbers in localized prostate cancer. The commercial and clinical question is whether favorable side-effect profiles can outweigh the lack of randomized comparisons and current guideline limits.
A STAT investigation found that Commure offers thousands of dollars in compensation to customers and other parties who refer its products to new business prospects. The report also says some customers experienced steep financial losses and other negative outcomes while the company argues its referral programs are standard and most customers are satisfied.
Workplace violence in healthcare settings remains a persistent challenge, with incidents often occurring despite the presence of scattered risk data. Experts argue that the true gap lies in the integration and visibility of risk indicators—an issue hospitals and systems must address to enhance prevention.
Beyond cavity prevention and gum health, dental care experts are looking at how the bite—jaw alignment and muscular function—shapes long-term oral wellness.
UnityPoint Health is leveraging artificial intelligence tools such as ambient scribing, capacity tracking, and AI-powered chart review to ease administrative burdens on clinicians.
A study from Elevance Health’s Public Policy Institute reveals that rural patients use telehealth far less than their urban counterparts, regardless of chronic condition or insurance status. The divide remains persistent even as telehealth becomes more mainstream.
Assured Health’s $19 million funding round signals a growing reliance on AI to streamline the cumbersome process of provider credential verification and insurance enrollment.
Ambient scribe developer Nabla has named Brian Manning as CEO, signaling a renewed focus on capturing greater market share in the burgeoning and highly competitive AI scribe environment.
